Eli Lilly expanded its AI-driven drug development footprint by signing a commercialization and discovery collaboration with Insilico Medicine. Lilly will pay $115 million upfront and can make milestone payments totaling up to $2.75 billion, with tiered royalties on commercial sales if candidates reach approval. Under the agreement, Insilico will grant Lilly rights to develop and commercialize experimental preclinical oral therapeutics across multiple therapeutic areas. The deal builds on an earlier Lilly-Insilico licensing and collaboration framework, extending it toward a broader pipeline contribution rather than software-only integration. For the broader biotech market, the structure highlights how big pharma is increasingly using AI-focused companies as external discovery engines. It also signals continuing pressure on traditional drug R&D timelines, with milestone-heavy economics designed to transfer development risk while keeping upside tied to regulatory and commercial success.